CY1112122T1 - Συνθεση σφαιριδιου λιποϊκου οξεος - Google Patents

Συνθεση σφαιριδιου λιποϊκου οξεος

Info

Publication number
CY1112122T1
CY1112122T1 CY20111100670T CY111100670T CY1112122T1 CY 1112122 T1 CY1112122 T1 CY 1112122T1 CY 20111100670 T CY20111100670 T CY 20111100670T CY 111100670 T CY111100670 T CY 111100670T CY 1112122 T1 CY1112122 T1 CY 1112122T1
Authority
CY
Cyprus
Prior art keywords
lipoic acid
composition
bullet
acid bullet
pellets
Prior art date
Application number
CY20111100670T
Other languages
English (en)
Inventor
Paolo Magri'
Antonio Nardi
Annibale Salvi
Flavio Villani
Original Assignee
Laboratorio Chimico Internazionale S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Chimico Internazionale S.P.A. filed Critical Laboratorio Chimico Internazionale S.P.A.
Publication of CY1112122T1 publication Critical patent/CY1112122T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

Η παρούσα εφεύρεση αφορά μία νέα σύνθεση βασιζόμενη σε σφαιρίδια λιποϊκού οξέος σε ένα λιπόφιλο μέσο, εάν είναι αναγκαίο συνδυασμένο με άλλα δραστικά συστατικά.
CY20111100670T 2007-10-23 2011-07-11 Συνθεση σφαιριδιου λιποϊκου οξεος CY1112122T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002051A ITMI20072051A1 (it) 2007-10-23 2007-10-23 Composizione a base di pellet di acido lipoico
EP08840866A EP2217220B1 (en) 2007-10-23 2008-10-23 Lipoic acid pellet composition

Publications (1)

Publication Number Publication Date
CY1112122T1 true CY1112122T1 (el) 2015-11-04

Family

ID=40313864

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100670T CY1112122T1 (el) 2007-10-23 2011-07-11 Συνθεση σφαιριδιου λιποϊκου οξεος

Country Status (27)

Country Link
US (1) US9820948B2 (el)
EP (1) EP2217220B1 (el)
JP (1) JP5626890B2 (el)
KR (1) KR101599078B1 (el)
CN (1) CN101861144B (el)
AT (1) ATE506053T1 (el)
AU (1) AU2008315667B2 (el)
BR (1) BRPI0816587A2 (el)
CA (1) CA2703152C (el)
CY (1) CY1112122T1 (el)
DE (1) DE602008006454D1 (el)
DK (1) DK2217220T3 (el)
ES (1) ES2363880T3 (el)
HR (1) HRP20110453T1 (el)
IL (1) IL205211A (el)
IT (1) ITMI20072051A1 (el)
MX (1) MX2010004481A (el)
NZ (1) NZ584884A (el)
PL (1) PL2217220T3 (el)
PT (1) PT2217220E (el)
RS (1) RS51712B (el)
RU (1) RU2501558C2 (el)
SI (1) SI2217220T1 (el)
TN (1) TN2010000163A1 (el)
UA (1) UA100394C2 (el)
WO (1) WO2009053824A1 (el)
ZA (1) ZA201002777B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
WO2011099031A1 (en) 2010-02-11 2011-08-18 Zota Health Care Limited Active antioxidants for all age group
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20130045273A1 (en) * 2011-08-19 2013-02-21 John Cuomo Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds
CA2965671A1 (en) * 2014-10-24 2016-04-28 Robert Shorr Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
US20200101043A1 (en) * 2016-12-14 2020-04-02 Cidat, S.A. De C.V. Combinations and methods for the treatment of neuropathic pain
CN106729725A (zh) * 2017-03-21 2017-05-31 北京百慧生化制药有限责任公司 硫辛酸作为抗氧化剂在多烯酸乙酯制剂或蛹油α‑亚麻酸乙酯制剂中的应用
IT202200007232A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
WO2023199241A1 (en) * 2022-04-12 2023-10-19 URIACH ITALY S.r.l. Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774166B2 (ja) * 1987-02-06 1995-08-09 信越化学工業株式会社 徐放性被覆薬剤の製造方法
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6479069B1 (en) 1999-09-23 2002-11-12 Juvenon, Inc. Nutritional supplement for increased energy and stamina
AU2002230543A1 (en) * 2000-11-02 2002-05-15 Nutrition 21, Inc. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
ITMI20012732A1 (it) * 2001-12-20 2003-06-20 Health Pharma S R L Integratore alimentare per neuropatici
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
CN1694695A (zh) * 2002-11-07 2005-11-09 帝斯曼知识产权资产管理有限公司 包含表没食子儿茶素没食子酸酯的新颖的营养药物性组合物
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US20060182729A1 (en) * 2005-02-17 2006-08-17 Prasad Kedar N Combat/training antioxidant micronutrient formulation and method of administration
JP2006298831A (ja) * 2005-04-21 2006-11-02 Sumitomo Shoji Chemicals Co Ltd αリポ酸粉体被覆物及びその製造方法、並びにαリポ酸含有食品
JP5157001B2 (ja) * 2005-04-30 2013-03-06 ビーエイチエヌ株式会社 安定化α−リポ酸組成物及びその利用
US20060270625A1 (en) * 2005-05-13 2006-11-30 Eastern Virginia Medical School Nutraceuticals for the treatment of neuropathy
JP5085329B2 (ja) * 2005-09-12 2012-11-28 協和発酵バイオ株式会社 α−リポ酸含有組成物
US20100239549A1 (en) * 2006-04-26 2010-09-23 Dpi Solutions, Inc. Alpha lipoic acid capsule composition stabilized in water phase and method for preparing the same
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico

Also Published As

Publication number Publication date
TN2010000163A1 (en) 2011-11-11
ATE506053T1 (de) 2011-05-15
US20110129442A1 (en) 2011-06-02
ITMI20072051A1 (it) 2009-04-24
JP5626890B2 (ja) 2014-11-19
CN101861144B (zh) 2013-03-13
RS51712B (en) 2011-10-31
US9820948B2 (en) 2017-11-21
AU2008315667A1 (en) 2009-04-30
ZA201002777B (en) 2011-06-29
AU2008315667B2 (en) 2013-02-28
CA2703152A1 (en) 2009-04-30
RU2501558C2 (ru) 2013-12-20
EP2217220B1 (en) 2011-04-20
DK2217220T3 (da) 2011-08-01
NZ584884A (en) 2011-11-25
CA2703152C (en) 2016-02-23
IL205211A (en) 2013-01-31
EP2217220A1 (en) 2010-08-18
JP2011500784A (ja) 2011-01-06
SI2217220T1 (sl) 2011-06-30
HRP20110453T1 (hr) 2011-07-31
IL205211A0 (en) 2010-12-30
DE602008006454D1 (de) 2011-06-01
WO2009053824A1 (en) 2009-04-30
MX2010004481A (es) 2010-08-02
ES2363880T3 (es) 2011-08-18
UA100394C2 (en) 2012-12-25
KR20100089848A (ko) 2010-08-12
KR101599078B1 (ko) 2016-03-02
PL2217220T3 (pl) 2011-09-30
CN101861144A (zh) 2010-10-13
BRPI0816587A2 (pt) 2015-03-03
PT2217220E (pt) 2011-07-13
RU2010120706A (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
CY1112122T1 (el) Συνθεση σφαιριδιου λιποϊκου οξεος
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
WO2008019871A3 (de) Neue salze des wirkstoffs rasagilin
BRPI0907036A2 (pt) Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
TR201907828T4 (tr) Geni̇ş spektrumlu bi̇r anti̇-mi̇krobi̇yel ajan
BRPI0814031A2 (pt) Composições antimicrobianas de ácido peroxicarboxílico prontas para o uso, com corrosão reduzida, estáveis em prateleira.
ATE555156T1 (de) Sauerstofffänger-mischungen
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
BRPI0915289A2 (pt) inserto para solas, sola, e, calçado.
EA201100286A1 (ru) Композиция кветиапина
DK2478054T3 (da) Polyamidsammensætning, som indeholder polyamid 4,10
DK2219662T3 (da) Aktive, opløselige, post-translationelt modificerede neuregulin- isoformer.
CL2012001159A1 (es) Composicion que comprende un inhibidor de alfa-1-proteinasa (api), y como minimo, un aminoacido; kit que comprende dicha composicion que se utiliza como una composicion farmaceutica adecuada para administracion intravenosa.
CR20120521A (es) Combinaciones de principios activos
BRPI0911556A2 (pt) eletrodo enzimático, e, célula de combustível.
MX2008009830A (es) Efecto del inhibidor bst2.
WO2009075329A1 (ja) 分解性を調整したゼラチン組成物
BRPI0906343A2 (pt) composições de pentafluoretano, tetraflueoretano e n-butano.
FR2902783B1 (fr) Compositions pyrotechniques thermo-initiables, utilisation.
BRPI0719836A2 (pt) Clonagem, expressão e uso de fosfolipases ácidas.
ATE556446T1 (de) Batterieanoden
BRPI0816810A2 (pt) utilização de pelo menos um composto, e, composto.
RU2009149491A (ru) 2,3-дихлор-4-[(6-хлор-5-циано-4-метилпиридил-2)-метилгидразоно]-бутен-2-овая кислота в качестве антидота 2,4-д на подсолнечнике